Literature DB >> 12741347

[Multicentric study for evaluation of levofloxacin in the treatment of complicated urinary tract infections].

Alberto Trinchieri1, Federico Marchetti.   

Abstract

OBJECTIVES: The objective of this open-label, single-arm, multicenter study was to assess the efficacy and safety of levofloxacin in the treatment of complicated urinary tract infections.
MATERIALS AND METHODS: A total of 72 outpatients with symptoms/signs of urinary tract infection and underlying anatomic or functional abnormality of the urinary tract was enrolled to receive levofloxacin 250 mg orally once daily for 10 days. Return visits were scheduled at 3-5 days (early follow-up visit) and 4-6 weeks after completion of therapy (long-term follow-up). At each visit symptoms and signs were assessed, possible adverse events were recorded and a urine specimen was obtained for culture.
RESULTS: At 3-5 days post-therapy clinical success rate was 94% and the overall microbiological eradication rate of pathogens was 94%. Microbiological eradication rate with respect to patients was 86%. Treatment failed in 4 patients and 2 patients had superinfections with pathogens still susceptible to levofloxacin. At long-term follow-up visit 3 reinfections were observed in patients previously cured at early follow-up. Drug-related adverse events were reported by 2 patients.
CONCLUSION: These study results indicate that levofloxacin 250 mg orally once daily for 10 days is an effective and well tolerated treatment of complicated urinary tract infections.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12741347

Source DB:  PubMed          Journal:  Arch Ital Urol Androl        ISSN: 1124-3562


  1 in total

1.  Fasting metabolism modulates the interleukin-12/interleukin-10 cytokine axis.

Authors:  Johannes J Kovarik; Elisabeth Kernbauer; Markus A Hölzl; Johannes Hofer; Guido A Gualdoni; Klaus G Schmetterer; Fitore Miftari; Yury Sobanov; Anastasia Meshcheryakova; Diana Mechtcheriakova; Nadine Witzeneder; Georg Greiner; Anna Ohradanova-Repic; Petra Waidhofer-Söllner; Marcus D Säemann; Thomas Decker; Gerhard J Zlabinger
Journal:  PLoS One       Date:  2017-07-24       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.